Let's get the number on the table first: 13.2 months versus 6.7 months. That's how long patients with metastatic pancreatic cancer lived on Revolution Medicines' new pill, daraxonrasib, compared with standard chemotherapy, in the Phase 3 trial that just won it FDA approval (RevMed). Roughly double the survival, from a once-daily tablet.

On August 26, the FDA approved the drug — brand name RASONQUE — for adults with metastatic pancreatic adenocarcinoma who have already been through at least one round of treatment, or who can't tolerate the brutal multi-drug chemo regimens (RevMed). It's the first medicine to directly hit the RAS protein family across a broad range of mutations in this cancer, a target drug developers have chased and missed for four decades.

The catch arrives fast: the list price is $39,800 a month, or about $477,000 a year — more than double the sticker price of Keytruda, the best-selling cancer drug on the planet (Yahoo Finance).

So here's the thesis: the hardest target in cancer biology finally cracked — and the bill for cracking it is now the story.

🧠 Why This Matters

Pancreatic cancer is one of the diagnoses oncologists dread most. An estimated 67,530 Americans will be diagnosed this year and 52,740 will die of it, and the five-year survival rate has been stuck at 13% for three straight years while the number for all cancers combined has climbed to about 70% (PanCAN). It's the third-leading cause of cancer death in the U.S. and on track to become the second by 2030.

The reason it's so lethal comes down to one villain. Around 90% of pancreatic tumors are driven by a mutated RAS gene, most often KRAS. RAS was labeled "undruggable" for years because the protein is smooth and slippery, with no obvious pocket for a drug to grab. Earlier KRAS inhibitors could only lock onto one specific mutation, KRAS G12C, which shows up in a sliver of pancreatic cases.

Daraxonrasib takes a different swing. It's a RAS(ON) multi-selective inhibitor that targets the active, switched-on form of the protein across multiple mutations at once — no companion diagnostic test required before you prescribe it (RevMed). For a disease where treatment options have barely moved in a generation, hitting the main engine directly is the shift that matters.

📊 Deep Dive

The approval rests on RASolute 302, a 500-patient Phase 3 trial that pitted the once-daily 300 mg pill against chemotherapy in previously treated metastatic pancreatic cancer (Dana-Farber). Here's how the pill stacked up against the standard of care:

  • Overall survival: 13.2 months vs. 6.7 months — a hazard ratio of 0.40, meaning a 60% reduction in the risk of death (RevMed).
  • Progression-free survival: 7.2 months vs. 3.6 months — the cancer took twice as long to grow.
  • Objective response rate: 31.6% vs. 11.2% — nearly three times as many tumors shrank (Dana-Farber).
  • Time to symptom deterioration: 5.7 months vs. 2.6 months — patients felt worse later, not sooner.
  • Form factor: a pill you take at home, not an infusion chair.
"The FDA approval of RASONQUE is a monumental step forward for patients with pancreatic cancer and for the oncology field."
— Mark A. Goldsmith, M.D., Ph.D., CEO, Revolution Medicines (RevMed)

Doubling survival sounds modest until you remember the baseline. Going from under seven months to over thirteen, in a cancer where few patients survive past a year, is the kind of jump this field almost never sees.

⚠️ The Catch

Start with the math. Median survival of 13.2 months is a genuine leap over 6.7 — and it's still 13.2 months. This is a drug that extends life, not one that cures the disease. For most patients it buys time, measured in months, not a clean bill of health.

Then there's the price. At $39,800 a month, a year of daraxonrasib runs to roughly $477,000 — north of twice what Keytruda lists for (Yahoo Finance). Revolution Medicines says eligible, commercially insured patients could pay as little as $0 out of pocket through its assistance program, and that Medicare Part D will cover some patients (Yahoo Finance). But co-pay cards and insurer negotiations don't erase a half-million-dollar sticker; they shuffle who pays it. Every payer covering this drug spreads that cost across premiums.

And the approval moved fast — the drug cleared the FDA roughly a month after Revolution filed its application (The Motley Fool). That speed reflects how badly this patient population needs options. It also means the long-tail safety and durability data will keep filling in after the drug is already in medicine cabinets.

🎯 What Happens Next

The approved label covers second-line and chemo-ineligible patients, but the bigger prize is first-line use — treating pancreatic cancer earlier, before it's been battered by chemo. Revolution is running trials there, and it's also testing daraxonrasib in lung and colorectal cancers, where RAS mutations are just as common. If the first-line data holds, the addressable population expands dramatically.

Wall Street has already priced in a big future. Analysts peg peak annual sales around $11.5 billion, and the stock has climbed more than 5x, pushing Revolution's valuation to roughly $47 billion (The Motley Fool). That's an enormous number resting on a drug that just launched — the market is betting the RAS franchise stretches well beyond pancreatic cancer.

"This approval gives physicians the confidence that directly inhibiting RAS can make a striking difference for patients."
— Brian M. Wolpin, M.D., M.P.H., RASolute 302 principal investigator, Dana-Farber Cancer Institute (RevMed)

🧩 Bigger Picture

RAS mutations don't stop at the pancreas. They drive a big share of lung and colorectal tumors too — two of the most common and deadly cancers there are. A drug that hits the active form of RAS across mutations, rather than one narrow variant, is a template that could ripple across oncology if the follow-on trials deliver.

That's the real weight of August 26. A target that spent 40 years in the "impossible" column now has an approved medicine sitting on top of it, with survival data to back it up. The open question is the one that's shadowing every cancer breakthrough now: a therapy that works is only half the fight when the price tag reads $477,000 a year.

Forty years to drug the undruggable. The science finally caught up. Now the checkbook has to.

Sources